Epidemiology and significance of surgical margins in the management of HPV-associated vulvar precancers (H-SIL) – analysis of own data

Česká verzia

Authors: T. Pichlík ^1,2 ; Lukáš Rob ¹ ; Michael Jiří Halaška ¹ ; J. Drozenová ³ ; H. Robová ¹
Authors place of work: Gynekologicko-porodnická klinika 3. LF UK a FNKV, Praha ¹; Lékařská fakulta, UK v Plzni ²; Ústav patologie 3. LF UK a FNKV, Praha ³
Published in the journal: Ceska Gynekol 2022; 87(6): 384-387
Category: Original Article
doi: https://doi.org/10.48095/cccg2022384

Summary

Objective: Epidemiology and evaluation of the importance of surgical margins in the treatment of vulvar H-SIL – analysis of own data. Material and methods: The prospective study included women diagnosed with HPV-associated vulvar epithelial neoplasia from 10/2016 to 1/2022. A total of 65 women were included. After surgical treatment, the women were distributed to groups according to surgical margins and were followed-up at regular intervals. Results: Seventeen women (26%) diagnosed with HPV-associated vulvar intraepithelial neoplasia were under 49 years, whereas 48 women (74%) were older than 49 years. Recurrence rates of HPV-associated precancers were 12.3%, 1.5% and 3.1% in excisions with positive margins up to 1 mm peripheral margins and 1–3 mm peripheral margins, respectively. The risk of recurrence when the lesion reaches the margin is statistically significant, compared to a healthy margin of 1–3 mm. Conclusion: Keeping the minimal healthy margin (1–3 mm) seems to be an acceptable risk of recurrence of HPV-associated vulvar intraepithelial neoplasia with positive cosmetic effect and minimal risk of disturbing the psychosexual functions of women. Long-term regular follow-up is necessary.

Keywords:

Epidemiology – vulvar intraepithelial neoplasia – H-SIL – surgical margins

Zdroje

1. Hudelo ML, Oury C. Dyskeratose erythroplasiforme de la muqueuse vulvaire. Bull Soc Franc Dermatol Et Syph 1922; 29: 139–142.

2. Ševčík L, Škapa P, Vantuchová Y et al. Dlaždicobuněčné prekancerózy vulvy. Historie a současný stav problematiky. Ceska Gynekol 2016; 81 (3): 172–176.

3. Bornstein J, Bogliatto F, Haefner HK et al. ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Obstet Gynecol 2016; 127 (2): 264–268. doi: 10.1097/AOG.0000 000000001285.

4. Yang EJ, Kong CS, Longacre TA. Vulvar and anal intraepithelial neoplasia: terminology, diagnosis, and ancillary studies. Adv Anat Pathol 2017; 24 (3): 136–150. doi: 10.1097/PAP.00000 00000000149.

5. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3,322 published patients. Gynecol Oncol 2005; 97 (2): 645–651. doi: 10.1016/j.ygyno.2005.02.012.

6. Ioffe YJ, Erickson BK, Foster KE et al. Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol 2013; 129 (3): 528–532. doi: 10.1016/j.ygyno.2013.02.033.

7. Likes WM, Stegbauer C, Tillmanns T et al. Correlates of sexual function following vulvar excision. Gynecol Oncol 2007; 105 (3): 600–603. doi: 10.1016/j.ygyno.2007.01.027.

8. Green MS, Naumann RW, Elliot M et al. Sexual dysfunction following vulvectomy. Gynecol Oncol 2000; 77 (1): 73–77. doi: 10.1006/gyno. 2000.5745.

9. Todd RW, Luesley DM. Medical management of vulvar intraepithelial neoplasia. J Low Genit Tract Dis 2005; 9 (4): 206–212. doi: 10.1097/01.lgt.0000179858.21833.0d.

10. Hillemanns P, Wang X, Staehle S et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO (2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006; 100 (2): 271–275. doi: 10.1016/j.ygyno.2005.08.012.

11. Lebreton M, Carton I, Brousse S et al. Vulvar intraepithelial neoplasia: classification, epidemiology, diagnosis, and management. J Gynecol Obstet Hum Reprod 2020; 49 (9): 101801. doi: 10.1016/j.jogoh.2020.101801.

12. Hoang LN, Park KJ, Soslow RA. Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology 2016; 48 (4): 291–302. doi: 10.1016/j.pathol.2016.02.015.

13. van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol 2008; 68 (2): 131–156. doi: 10.1016/j.critrevonc.2008.02. 012.

14. Satmary W, Holschneider CH, Brunette LL et al. Vulvar intraepithelial neoplasia: risk factors for recurrence. Gynecol Oncol 2018; 148 (1): 126–131. doi: 10.1016/j.ygyno.2017.10.029.

15. Preti M, Scurry J, Marchitelli CE et al. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol 2014; 28 (7): 1051–1062. doi: 10.1016/j.bpobgyn.2014.07.010.

16. Ahr A, Rody A, Kissler S et al. Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III). Zentralbl Gynakol 2006; 128 (6): 347–351. doi: 10.1055/s-2006-942280.

17. Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. Int J Gynaecol Obstet 2021; 155 (Suppl 1): 7–18. doi: 10.1002/ijgo.13881.

18. Judson PL, Habermann EB, Baxter NN et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107 (5): 1018–1022. doi: 10.1097/01.AOG.000021026 8.57527.a1.

19. Joura EA, Lösch A, Haider-Angeler MG et al. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 2000; 45 (8): 613–615.

20. Thuijs NB, van Beurden M, Bruggink AH et al. Vulvar intraepithelial neoplasia: incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer 2021; 148 (1): 90–98. doi: 10.1002/ijc.33198.

21. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005; 106 (6): 1319–1326. doi: 10.1097/01.AOG.0000187301.76283.7f.

22. Modesitt SC, Waters AB, Walton L et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet Gynecol 1998; 92 (6): 962–966. doi: 10.1016/s0029-7844 (98) 00350-0.

23. Terlou A, van Seters M, Ewing PC et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 2011; 121 (1): 157–162. doi: 10.1016/ j.ygyno.2010.12.340.

24. Trutnovsky G, Reich O, Joura EA et al. Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial. Lancet 2022; 399 (10337): 1790–1798. doi: 10.1016/S0140- 6736 (22) 00469-X.